The Aim of this analysis is systematization of trials different stents in patient with atherosclerotic coronary stenoses of coronary arteries and diabetes mellitus.

The purpose of the study is a comparative assessment of the immediate and long-term results using Sirolimus - Eluting Stents (SES) and Bare-Metal Stent (BMS) in patients with unstable angina and diabetes mellitus type 2.

Main aim of the clinical study was estimate the clinical and laboratory factors purchase behaviour on to course the ischemic heart disease.

Aim. To assess the effectiveness of endovascular treatment of in-stent restenosis after successful chronic total coronary occlusion (CTO) recanalization.Methods. 117 patients who underwent successful CTO recanalization in the period from 2009 to 2012 were included in the study. All patients were referred to the elective examination including coronary angiography, intravascular ultrasound and optical coherence tomography within 6.1±0.9 months after the successful recanalization. If in-stent restenosis after CTO recanalization was confirmed and further endovascular treatment was performed, patients underwent repeat endovascular examination after 6.6±0.8 months. Сoronary artery lumen was evaluated at the sites of the performed intervention.Results. 18.8% of patients had in-stent restenosis, of them 95.5% underwent percutaneous coronary intervention. 76.2% of patients underwent high-pressure balloon predilatation, 4.8% of patients received paclitaxel-eluting balloons, 14.2% of patients – drug-eluting stents (DES), and 4.8% of patients - bare-metal stents. A significant increase of minimum lumen diameter after the percutaneous coronary intervention (from 0.8±0.5 mm to 2.2±0.3 mm, p<0.01) and a decrease of coronary artery lumen stenosis (from 67.9±18.3% to 19.7±8.8%, p<0.01) had been determined. There were no cases of death, acute myocardial infarction, acute strokes and target lesion thrombosis 6.6±0.8 months after the in-stent restenosis treatment. 52.8% of cases had repeat restenosis, including 56.3% of those who underwent high-pressure balloon predilatation and 33.3% of patients after DES implantation. The minimum lumen diameter decreased from 2.2±0.3 mm to 1.6±0.5 mm (p<0.01), and the degree of lumen stenosis increased from 19.7±8.8 mm2 to 41.5±17.3 mm2 (p<0.01).Conclusion. In-stent restenosis treatment after the successful CTO recanalization by the endovascular methods was effective in 47.2% of cases. DES and drug coated balloons can potentially reduce the rate of repeat restenosis.

Objective. To determine the clinical and genetic risk factors for the development and progression of carotid vascular remodeling according to the prospective observation after five years in patients with essential arterial hypertension (AH). Material and methods. The repeat clinical and instrumental examination with assessment of concomitant cardiovascular risk factors (obesity, smoking, alcohol consumption, physical activity level, hyperglycemia, hypercholesterolemia, signs of depression) was performed in 78 patients with AH. The ultrasound examination of carotid arteries included evaluation of intima-media complex thickness (IMT) and the presence of atherosclerotic plaques. The polymorphism of the genes of the renin-angiotensin-aldosterone system analyzed by polymerase chain reaction and polymorphism of restriction fragment lengths. Results. Progression of vascular remodeling was observed in 26 patients (33.3%) according to the results of carotid arteries examination after 5 years. Age (r=0.53; p=0.001), degree of AH (r=0.43; p=0.0001), level of office systolic blood pressure (r=0.295; p=0.0090), presence of the mutant C allele polymorphism A1166C of the angiotensin II type 1 receptor gene - AGTR1 (r=0.387; p=0.0001), blood glucose (r=0.30; p=0.010), waist circumference (r=0.258; p=0.023) were associated with an increase IMT common carotid artery (CCA) in patients with AH. The multiple linear regression analysis identified independent factors influencing on the IMT CCA - age (b=0.62; p=0.01), males (b=0.321; p=0.01) and the mutant C allele carrier polymorphism A1166C of AGTR1 gene (b=0.312; p=0.01). Conclusions. The progression of carotid vascular remodeling risk factors in patients with AH were age, male gender and polymorphism of A1166C gene AGTR1.